Emanuele Alì

Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions

Background/Objectives: CD20×CD3 bispecific antibodies (BsAbs) have changed the management of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Whether and how radiotherapy (RT) can be safely and usefully combined with BsAb therapy remains undefined. This Perspective reviews...